Department of Orthopaedics, Macclesfield District General Hospital, East Cheshire NHS Trust, Macclesfield, UK.
J Clin Pharm Ther. 2013 Apr;38(2):159-61. doi: 10.1111/jcpt.12013. Epub 2012 Nov 20.
Rivaroxaban is an oral anticoagulant, currently licensed for use as a venous thromboembolism (VTE) prophylaxis, and recommended by the National Institute for Clinical Excellence (NICE) for all patients undergoing elective hip and knee replacement surgery in the UK. We present the first case of a suspected hypersensitivity to rivaroxaban.
A 57-year-old man with no previous allergies underwent an uncomplicated, elective partial knee replacement, after which he was prescribed a routine 2-week course of rivaroxaban 10 mg. He developed an allergic response requiring readmission for assessment and treatment 7 days post-operatively.
We believe this to be the first published case of hypersensitivity associated with rivaroxaban. More research is needed to determine this association. At the same time, given the growing range and increasing use of anticoagulants, particular vigilance is required regarding potential side effects so that these may be managed quickly and effectively in the early stages.
利伐沙班是一种口服抗凝剂,目前获准用于预防静脉血栓栓塞症(VTE),英国国家卫生与临床优化研究所(NICE)推荐所有择期髋关节和膝关节置换手术的患者使用。我们报告首例疑似对利伐沙班过敏的病例。
一名 57 岁男性,无既往过敏史,接受了一次无并发症的择期部分膝关节置换术,术后常规开具了 2 周疗程的利伐沙班 10mg。他在术后 7 天出现过敏反应,需要再次入院评估和治疗。
我们认为这是首例与利伐沙班相关的过敏反应报道。需要进一步研究来确定这种关联。同时,鉴于抗凝剂的应用范围越来越广,使用越来越多,需要特别注意潜在的副作用,以便在早期阶段快速有效地进行管理。